ORX 489
Alternative Names: ORX-489Latest Information Update: 02 Jan 2025
Price :
$50 *
At a glance
- Originator Centessa Pharmaceuticals
- Class Behavioural disorder therapies; Small molecules
- Mechanism of Action Orexin receptor type 2 agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Neurodegenerative disorders; Neurological disorders; Psychiatric disorders
Most Recent Events
- 12 Nov 2024 Preclinical trials in Neurodegenerative disorders in USA (PO) prior to November 2024
- 12 Nov 2024 Preclinical trials in Neurological disorders in USA (PO) prior to November 2024
- 12 Nov 2024 Preclinical trials in Psychiatric disorders in USA (PO) prior to November 2024